Finding a cure for inflammatory bowel disease (IBD) would mean reducing treatment waste, according to Ashwin N.

Thetis Pharmaceuticals LLC ("Thetis"), a clinical-stage company developing TP-317, a first-in-class, small molecule drug candidate targeting the BLT1 receptor to treat inflammatory bowel disease (IBD) ...